Emcure Pharmaceuticals schedules 45th AGM for September 21, 2026

1 min read | Published on 28 Aug 2026, 08:45 PM |Updated on 28 Aug 2026, 08:45 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Emcure Pharmaceuticals schedules 45th AGM for September 21, 2026
Meeting to be held via video conferencing without physical presence
Remote e-voting runs from September 18 to September 20, 2026
Record date for attendance eligibility is September 14, 2026

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals has scheduled its 45th Annual General Meeting (AGM) for Monday, September 21, 2026. The company will hold the event through video conferencing or other audio-visual means, in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India circulars.

The AGM is set to begin at 11:00 am IST. Shareholders holding shares as of the cut-off date, Monday, September 14, 2026, are eligible to attend via the MUFG Intime India Private Limited platform.

Voting Timeline

Remote e-voting will commence on Friday, September 18, 2026, at 9:00 am IST and conclude on Sunday, September 20, 2026, at 5:00 pm IST.

Event	Date	Time
Remote e-voting begins	September 18, 2026	9:00 am
Remote e-voting ends	September 20, 2026	5:00 pm
AGM date	September 21, 2026	11:00 am

Annual Report Availability

The Notice of the 45th AGM and the Annual Report for FY26 are available on the company’s website and the registrar’s portal. The filing was made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Amruta Yangalwar, Company Secretary & Compliance Officer, signed the disclosure on August 28, 2026.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.48%	-0.64%	-2.88%	+28.44%	+27.29%	0.0%

What specific strategic initiatives or capital allocation plans for FY27 are likely to be highlighted in Emcure's upcoming Annual Report?

How might the outcome of the AGM resolutions impact Emcure's dividend policy and shareholder returns in the near term?

Are there any anticipated changes to the board composition or executive compensation structures that shareholders should monitor during the e-voting period?

Emcure Pharmaceuticals

View Company Insights

View All News

Emcure Pharmaceuticals Receives US FDA Approval for Sanand Formulations Plant in Gujarat

0 min read | Published on 08 Aug 2026, 02:38 PM |Updated on 08 Aug 2026, 02:38 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Emcure Pharmaceuticals has obtained US FDA approval for its formulations plant in Sanand, Gujarat. The clearance from the United States Food and Drug Administration highlights the facility's compliance with international pharmaceutical manufacturing standards. This approval is a key regulatory milestone that strengthens Emcure Pharmaceuticals' manufacturing credentials for the US market.

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals has received approval from the United States Food and Drug Administration (US FDA) for its formulations plant situated in Sanand, Gujarat. This regulatory clearance represents a significant development for the company's manufacturing capabilities and its standing in the US pharmaceutical market.

US FDA Approval for Sanand Facility

The US FDA approval pertains to Emcure Pharmaceuticals' formulations plant located in Sanand, Gujarat. Receiving this clearance from one of the world's most stringent pharmaceutical regulatory bodies reflects the facility's adherence to the required manufacturing and quality standards.

Parameter:	Details
Regulatory Authority:	US FDA (United States Food and Drug Administration)
Facility Type:	Formulations Plant
Facility Location:	Sanand, Gujarat
Company:	Emcure Pharmaceuticals

Significance of the Approval

US FDA approval for a manufacturing facility is a critical requirement for pharmaceutical companies seeking to supply products to the United States market. The clearance of the Sanand formulations plant positions Emcure Pharmaceuticals to leverage this facility for its US-facing pharmaceutical operations, reinforcing the company's manufacturing credentials on an international scale.

Historical Stock Returns for Emcure Pharmaceuticals